Optimal Androgen Deprivation Therapy Combined with Proton Beam Therapy for Prostate Cancer: Results from a Multi-Institutional Study of the Japanese Radiation Oncology Study Group.
androgen deprivation therapy
prostate cancer
proton beam therapy
radiation therapy
risk classification
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
25 Jun 2020
25 Jun 2020
Historique:
received:
25
05
2020
revised:
19
06
2020
accepted:
23
06
2020
entrez:
8
7
2020
pubmed:
8
7
2020
medline:
8
7
2020
Statut:
epublish
Résumé
Androgen deprivation therapy (ADT) combined with radiation therapy benefits intermediate- and high-risk prostate cancer (PC) patients. The optimal ADT duration in combination with high-dose proton beam therapy (PBT) remains unknown. Intermediate- and high-risk PC patients treated with PBT combined with ADT for various durations were analyzed retrospectively. To assess the relationship between ADT and biochemical relapse-free (bRF) rate, Cox proportional hazards models including T stage, prostate specific antigen (PSA) level, Gleason score (GS), and total radiation dose were used. In the intermediate-risk PC patients ( Short-term (≤6 months) ADT is beneficial for intermediate-risk PC patients, but likely unnecessary for those with a single risk factor, whereas ADT for >6 months is necessary for high-risk PC patients and ADT for ≥21 months might be optimal for those with multiple risk factors in combination of high-dose PBT.
Sections du résumé
BACKGROUND
BACKGROUND
Androgen deprivation therapy (ADT) combined with radiation therapy benefits intermediate- and high-risk prostate cancer (PC) patients. The optimal ADT duration in combination with high-dose proton beam therapy (PBT) remains unknown.
METHODS
METHODS
Intermediate- and high-risk PC patients treated with PBT combined with ADT for various durations were analyzed retrospectively. To assess the relationship between ADT and biochemical relapse-free (bRF) rate, Cox proportional hazards models including T stage, prostate specific antigen (PSA) level, Gleason score (GS), and total radiation dose were used.
RESULTS
RESULTS
In the intermediate-risk PC patients (
CONCLUSIONS
CONCLUSIONS
Short-term (≤6 months) ADT is beneficial for intermediate-risk PC patients, but likely unnecessary for those with a single risk factor, whereas ADT for >6 months is necessary for high-risk PC patients and ADT for ≥21 months might be optimal for those with multiple risk factors in combination of high-dose PBT.
Identifiants
pubmed: 32630494
pii: cancers12061690
doi: 10.3390/cancers12061690
pmc: PMC7352923
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Japan Agency for Medical Research and Development
ID : 20ck0106494h0002
Références
Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):296-303
pubmed: 28463149
Int J Radiat Oncol Biol Phys. 2008 Mar 1;70(3):744-51
pubmed: 17904306
Urol Oncol. 2011 Jan-Feb;29(1):52-7
pubmed: 19523856
Prostate Cancer Prostatic Dis. 2016 Mar;19(1):57-62
pubmed: 26503109
Lancet Oncol. 2010 Nov;11(11):1066-73
pubmed: 20933466
J Clin Oncol. 2009 Jul 20;27(21):3452-8
pubmed: 19506162
Cancer Med. 2018 Mar;7(3):677-689
pubmed: 29441697
Lancet Oncol. 2015 Mar;16(3):320-7
pubmed: 25702876
N Engl J Med. 2009 Jun 11;360(24):2516-27
pubmed: 19516032
Cancer. 2008 Jan 1;112(1):55-60
pubmed: 17968996
Eur Urol. 2018 Oct;74(4):432-441
pubmed: 29980331
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Oncology (Williston Park). 2016 Mar;30(3):229-36
pubmed: 26984216
BMC Cancer. 2020 Jan 30;20(1):75
pubmed: 32000716
Cancer. 2016 Oct 15;122(20):3225-3231
pubmed: 27351298
Int J Urol. 2019 Oct;26(10):971-979
pubmed: 31284326
N Engl J Med. 2016 Oct 13;375(15):1415-1424
pubmed: 27626136
J Clin Oncol. 2015 Feb 1;33(4):332-9
pubmed: 25534388
Int J Radiat Oncol Biol Phys. 2011 Oct 1;81(2):390-6
pubmed: 20832180
Int J Radiat Oncol Biol Phys. 2014 Mar 1;88(3):596-602
pubmed: 24521677
Int J Radiat Oncol Biol Phys. 2013 Mar 15;85(4):1012-7
pubmed: 22981709
Int J Radiat Oncol Biol Phys. 2000 Jun 1;47(3):617-27
pubmed: 10837944
N Engl J Med. 2005 Jan 13;352(2):154-64
pubmed: 15647578